{"id":"NCT00974090","sponsor":"Mitsubishi Tanabe Pharma Corporation","briefTitle":"Efficacy and Safety Study of MP-513 in Combination With Sulfonylurea in Patients With Type 2 Diabetes","officialTitle":"A Phase III Study of MP-513 in Combination With Sulfonylurea in Japanese Patients With Type 2 Diabetes Mellitus","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-09","primaryCompletion":"2011-03","completion":"2011-03","firstPosted":"2009-09-10","resultsPosted":"2014-05-08","lastUpdate":"2014-05-08"},"enrollment":194,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Type 2 Diabetes Mellitus"],"interventions":[{"type":"DRUG","name":"Placebo / Teneli (Teneligliptin) + SU (Sulfonylurea)","otherNames":["MP-513","Amaryl","glimepiride"]},{"type":"DRUG","name":"Teneli / Teneli + SU","otherNames":["MP-513","Amaryl","glimepiride"]}],"arms":[{"label":"Placebo / Teneli + SU","type":"PLACEBO_COMPARATOR"},{"label":"Teneli / Teneli + SU","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to evaluate the safety and efficacy of MP-513 (Teneligliptin) in combination with Sulfonylurea in patients with type 2 Diabetes for 12 weeks administration and to evaluate the safety and efficacy of MP-513 in combination with Sulfonylurea with an extension treatment for up to 52 weeks.","primaryOutcome":{"measure":"Change From Baseline in HbA1c at Week 12","timeFrame":"at Week 0 and Week 12","effectByArm":[{"arm":"Placebo / Teneli + SU","deltaMin":0.29,"sd":0.06},{"arm":"Teneli / Teneli + SU","deltaMin":-0.71,"sd":0.06}],"pValues":[]},"eligibility":{"minAge":"20 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":7},"locations":{"siteCount":1,"countries":["Japan"]},"refs":{"pmids":["24205974"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":98},"commonTop":["Nasopharyngitis","Glucose urine present","Protein urine present","Hypoglycaemia","Upper respiratory tract inflammation"]}}